In short
Clinical trials are studying HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE in people with recently diagnosed stage 3 type 1 diabetes. The main goals are to check safety, tolerability, and whether the study treatment can slow loss of insulin-making cells in the pancreas.
Key points
- Clinical trials of HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE are focused on people with recently diagnosed stage 3 type 1 diabetes. The main study is a Phase 2 interventional trial with 190 planned participants. Researchers are looking at safety, tolerability, and whether the treatment can slow the loss of insulin-producing cells in the pancreas. The primary outcomes include health problems or side effects during the study and measures of pancreas function related to insulin production. The trial is authorised and uses an intravenous study treatment compared with sodium chloride.
Trial overview
The main trial in the data is the SAFEGUARD study, which stands for SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes. It is studying HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE in people with type 1 diabetes.
The study is authorised, which means it has been approved to move forward in the listed setting.
Who is being studied
This trial is for people who were recently diagnosed with stage 3 type 1 diabetes.
Stage 3 type 1 diabetes means the disease is already clearly present and diagnosed, and the study focuses on this early period after diagnosis.
Study design and phase
This is an interventional study, which means the researchers are giving a study treatment and then watching what happens.
The trial is in Phase 2, a stage where researchers look more closely at safety and begin to test whether the treatment may help the disease.
The planned enrollment is 190 people.
What researchers are measuring
The primary outcomes include recording and reviewing any health problems or side effects that happen during the study.
Researchers are also checking measures of pancreas function related to insulin production, which helps show whether the pancreas is still making insulin well.
The brief summary says the study wants to learn about safety and tolerability, and also find out whether the treatment can slow the decline of insulin-producing cells in the pancreas over the course of the study.
Treatment regimens in the study
The intervention list includes SAB-142 given by intravenous administration and a sodium chloride infusion used as the comparison treatment.
SAB-142 is named in the trial details as the study drug linked to HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE.
Why this trial matters
This study is trying to answer an important question: can treatment given soon after diagnosis help protect the pancreas in type 1 diabetes?
By focusing on safety, tolerability, and pancreas function, the trial is designed to show both how people handle the treatment and whether it may help preserve insulin-making cells.